<DOC>
	<DOCNO>NCT00613223</DOCNO>
	<brief_summary>Primary Objective : To determine maximum tolerate dose &amp; dose limiting toxicity vandetanib combine standard dose etoposide among patient recurrent malignant glioma &amp; enzyme-inducing anti-epileptic drug ( EIAEDs ) Secondary Objectives : To assess safety &amp; tolerability vandetanib + etoposide population ; To evaluate pharmacokinetics vandetanib among malignant glioma patient &amp; EIAEDs combine etoposide . Exploratory Objective : To evaluate evidence anti-tumor activity study regimen among recurrent malignant glioma patient include radiographic response rate , 6-month progression free survival ( PFS ) rate &amp; median PFS .</brief_summary>
	<brief_title>Ph I Dose Escalation Trial Vandetanib Combo w Etoposide Malignant Gliomas</brief_title>
	<detailed_description>This open-label , single center , 2-cohort phase I dose-escalation study vandetanib administer orally continuous daily dose schedule + oral etoposide among adult patient recurrent relapse malignant glioma . Patients stratify base whether receive EIAEDs &amp; stratum independently dose escalate . Dose vandetanib increase successive cohort patient . Etoposide give daily dose 50mg/day 21 day follow 7 day etoposide . Cohorts 3-6 subject accrue dose level maximum tolerate dose ( MTD ) define . Subjects adult patient histologically confirm malignant glioma presenting time recurrence/relapse . Up 48 subject enrol . Sample size base modify , classical `` 3+3 '' dose escalation design . Primary safety &amp; efficacy analysis conduct subject data time subject still receive study drug complete least 4 cycle treatment . Most common adverse event ( AEs ) associate vandetanib rash , diarrhea , &amp; asymptomatic QTc prolongation . Protracted oral dose etoposide associate toxicity mild patient &amp; consist mainly myelosuppression &amp; diarrhea . Less commonly , protract etoposide dose associate w significant hematologic toxicity .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Patients baseline evaluation ≤14days prior 1st dose study drug unless otherwise specify Patients confirm malignant glioma ( MG ) recurrence/relapse Patients may stereotactic tumor biopsy &lt; 1 week surgical resection open biopsy &lt; 4 week start study drug For stratum nonEIAED patient , patient must EIAEDs &gt; 2 week prior start study drug ; similarly stratum EIAED patient , patient must EIAED &gt; 2 week prior start study drug Patients nonincreasing dose steroid &gt; 7 day prior obtain baseline MRI gadolinium ( GdMRI ) brain Patients nonincreasing dose steroid &gt; 7 day prior start study drug Multifocal disease eligible Age ≥ 18 year Karnofsky Performance Status ( KPS ) ≥70 Absolute Neutrophil Count ≥1.0 x 10 9/L Hemoglobin ( Hgb ) ≥9 g/dL Platelets ≥100 x 10 9/L Serum creatinine ≤1.5 x ULRR measure 24hr CrCl ≥50mL/min/1.73m2 Life expectancy ≥ 12 week Written inform consent obtain prior screen procedure Negative BetaHCG pregnancy test woman childbearing potential Laboratory Results : Serum direct bilirubin &gt; 1.5 x upper limit normal ( ULN ) reference range Serum creatinine &gt; 1.5 x ULRR &amp; CrCl &lt; 30 mL/min Potassium , &lt; 4.0 mmol/L despite supplementation ; serum calcium , magnesium normal range despite supplementation ALT AST &gt; 2.5 x ULRR Evidence severe/uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol Clinically significant cardiovascular event myocardial infarction , superior vena cava syndrome , New York Heart Association classification heart disease &gt; 2 within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia History arrhythmia symptomatic/requires treatment/asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication exclude . Previous history QTc prolongation result medication require discontinuation medication Congenital long QT syndrome , 1st degree relative unexplained sudden death &lt; 40 year Presence leave bundle branch block QTc Bazett 's correction 's unmeasureable , ≥ 480msec screen EEG . Any concomitant medication may cause QTc prolongation , induce Torsades de Pointes/induce CYP3A4 function except EIAEDs Hypertension control medical therapy Currently active diarrhea may affect ability patient absorb study regimen/tolerate diarrhea Women currently pregnant/breast feed Previous current malignancy histology last year , exception cervical carcinoma situ &amp; adequately treat basal cell squamous cell carcinoma skin Receipt investigational agent &lt; 30 day prior commence study treatment unless pt recover anticipated toxicity investigational agent Last dose prior chemo discontinue &lt; 4 week start study therapy unless pt recover anticipated toxicity chemo Last XRT &lt; 4 week start study therapy , unless patient recover anticipated toxicity XRT Any unresolved toxicity &gt; CTC gr1 previous anticancer therapy Previous enrollment/randomization treatment present study Major surgery &lt; 4 weeks/incompletely heal surgical incision start study therapy Patients receive prior oral VEGFR , EGFR PDGFRdirected therapy . Patients receive prior Avastin eligible long least 6 week elapse since last dose . Patients take warfarin sodium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Malignant Gliomas</keyword>
	<keyword>Etopophos</keyword>
	<keyword>Toposar</keyword>
	<keyword>VePesid</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Zactima</keyword>
	<keyword>ZD6474</keyword>
	<keyword>VP-16</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Recurring Malignant Brain Tumor</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Glioma</keyword>
	<keyword>Malignant Glioma</keyword>
	<keyword>GBM</keyword>
</DOC>